Dermatomyositis is a rare systemic autoimmune disease in which the inflammatory process affects skeletal muscles and the skin. The condition is accompanied by progressive muscle weakness, characteristic skin rashes, and may involve internal organs, which requires timely and comprehensive therapy.
When is treatment for dermatomyositis required?
Treatment is required in cases of increasing muscle weakness, especially in the shoulder and pelvic girdles, difficulty climbing stairs, rising from a seated position, or lifting the arms. Typical skin manifestations include violaceous or pinkish rashes on the face, eyelids, hands, and elbows, as well as increased fatigue, muscle pain, and weight loss. Without treatment, the disease may lead to significant limitation of mobility and systemic complications.
How is dermatomyositis treated?
Therapy for dermatomyositis is aimed at suppressing autoimmune inflammation and preserving muscle function. The mainstay of treatment is systemic glucocorticosteroids with gradual dose adjustment. In moderate to severe cases, immunosuppressive agents and modern targeted therapies are used. Rehabilitation measures play an important role, including therapeutic exercise, physiotherapy, and structured recovery programs. Treatment is carried out under continuous monitoring of laboratory parameters and the condition of internal organs.
Treatment of dermatomyositis is provided in leading clinics in Belarus, where clinical expertise is combined with modern pharmacological therapy and long-term medical follow-up programs. Individualized treatment selection and multidisciplinary care help achieve sustained remission, slow disease progression, and maintain patients’ quality of life.
